VISUDYNE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VISUDYNE (VISUDYNE).
Verteporfin, a benzoporphyrin derivative, is a photosensitizer activated by nonthermal red light (689 nm). Upon activation, in the presence of oxygen, it generates reactive oxygen species (e.g., singlet oxygen) causing local damage to endothelial cells, leading to occlusion of abnormal choroidal neovasculature.
| Metabolism | Metabolized via liver by non-specific esterases to active metabolite benzoporphyrin derivative diacid (BPD-DA); further metabolism minimal; eliminated primarily in feces via biliary excretion. |
| Excretion | Biliary/fecal: >90% unchanged; renal: <1% |
| Half-life | 5-6 hours (verteporfin); clinical context: supports once-daily dosing for photodynamic therapy |
| Protein binding | >90% bound to plasma lipoproteins (HDL and LDL) |
| Volume of Distribution | 0.5-1.5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Intravenous: 100% (only route of administration) |
| Onset of Action | Intravenous: within 15 minutes of light activation |
| Duration of Action | Photosensitivity persists 24-48 hours after infusion; advise patients to avoid sunlight and bright indoor light during this period |
| Molecular Weight | 718.79 |
| Action Class | Vascular endothelial growth factor (VEGF) inhibitor for AMD |
6 mg/m2 body surface area administered as a 10-minute intravenous infusion, followed by laser light activation at 689 nm 15 minutes after start of infusion.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; no specific GFR-based guidelines established. |
| Liver impairment | Use with caution in moderate hepatic impairment (Child-Pugh class B); no specific dose modification established. Contraindicated in severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | Safety and efficacy not established for pediatric patients; no weight-based dosing guidelines available. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients aged 65-89 years with no observed differences in safety or efficacy. |
| 1st trimester | Contraindicated; embryotoxic and teratogenic in animal studies. |
| 2nd trimester | Contraindicated; no adequate human data, potential risks. |
| 3rd trimester | Contraindicated; may cause fetal harm due to photodynamic therapy effects. |
Clinical note
Comprehensive clinical and safety monograph for VISUDYNE (VISUDYNE).
| Placental transfer | Unknown in humans; verteporfin is a lipophilic photosensitizer that may cross the placenta based on molecular weight and animal data. |
| Breastfeeding | Not recommended during breastfeeding; systemic exposure from maternal photodynamic therapy is minimal but no data on excretion into breast milk. Avoid until at least 96 hours post-infusion. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to verteporfin or any component of the formulationPorphyriaActive infections or wounds in the treatment areaSignificant hepatic impairment
| Precautions | Photosensitivity: Patients may become sensitive to sunlight or bright indoor light for 5 days after infusion; avoid exposure., Extravasation: Can cause severe pain, inflammation, or necrosis at injection site; ensure proper IV administration., Ocular safety: Treatment is only for eyes with subfoveal CNV; not for occult CNV without classic component., Hepatic impairment: Use caution in moderate to severe hepatic impairment; may increase systemic exposure., Anaphylaxis: Severe allergic reactions reported; monitor during infusion., Vision loss: Transient or permanent decrease in visual acuity may occur. |
| Food/Dietary | No specific food restrictions are required. However, patients should avoid consuming foods or beverages that contain photosensitizing agents (e.g., furocoumarins in grapefruit, celery, figs) during the photosensitivity period (5 days post-infusion) to theoretically reduce risk of enhanced phototoxicity. Alcohol does not interact directly but may impair vision; thus, caution is advised. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | Visudyne (verteporfin) is contraindicated in pregnancy. Animal studies show fetal harm (ossification delays, malformations) at clinically relevant doses. No adequate human data; risk in all trimesters is high. |
| Fetal Monitoring | Pregnancy test before treatment. Monitor liver function and photosensitivity reactions. Fetal ultrasound if exposure occurs. |
| Fertility Effects | No specific human fertility data. Animal studies show no impairment of fertility at clinically relevant doses. |
| Clinical Pearls | Visudyne (verteporfin) is a photosensitizer used in photodynamic therapy (PDT) for predominantly classic subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) and pathologic myopia. Infuse over 10 minutes at a dose of 6 mg/m2 body surface area, followed by laser activation at 689 nm (nonthermal) 15 minutes after start of infusion. Avoid extravasation due to risk of severe local pain, inflammation, and necrosis. Patient must avoid direct sunlight or bright indoor light for 5 days post-infusion as photosensitivity persists. Re-treatment is possible every 3 months if CNV leakage recurs. Caution in moderate to severe hepatic impairment due to lack of safety data. |
| Patient Advice | This drug makes your skin and eyes sensitive to light for at least 5 days after treatment. · Avoid direct sunlight, bright indoor lights (e.g., tanning lamps, halogen lamps), and even sunlight through windows. · Wear dark sunglasses and protective clothing (long sleeves, pants, hat) when outdoors. · Do not stay in the dark; normal indoor lighting is safe, but avoid very bright settings. · Seek immediate medical attention if you experience severe pain, redness, or blistering of the skin. · You may have temporary vision changes, including blurred vision or visual disturbances (e.g., flashes of light). · Avoid driving or operating machinery until your vision clears. · Report any sudden vision loss, floaters, or flashing lights to your doctor. · Follow-up appointments are necessary to check the response to treatment. · Do not use any other medications, including over-the-counter products, without consulting your doctor. |